findmyKOL

Geoffrey Block, MD

Enriched profile

Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs · U.S. Renal Care

ORCIDNPI
Region🇺🇸 Lone Tree, CO · West · United StatesSpecialtyNephrologyFocusParathyroid Disorders and Treatments+4
Active KOLfindmyKOL typefindmyKOL type: our influence ranking, shown when you reveal the full profileLatest publication2026Online presenceNone verifiedPayments2021–2025NIH fundingNone on fileWhy? →

Geoffrey Block is Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs at U.S. Renal Care. OpenAlex indexes 287 publications with 23,163 citations (h-index 62); ClinicalTrials.gov lists 13 registered studies with this person as an investigator. By OpenAlex citation count, this profile ranks in the top 5% of Nephrology profiles in the findmyKOL directory.

Data verified 14 Aug 2026

Overview

Updated 27 Aug 2026

Geoffrey A. Block, MD, is Associate Chief Medical Officer & Senior Vice President, Clinical Research & Medical Affairs at U.S. Renal Care. The public record shows 287 publications with 23,163 citations (h-index 62), centered on Parathyroid Disorders and Treatments, Dialysis and Renal Disease Management, Magnesium in Health and Disease. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 10 companies.

  • Most recent indexed publication: 2026 · Kidney360
  • Top research focus: Parathyroid Disorders and Treatments
  • 13 registered trials on ClinicalTrials.gov
  • Open Payments reporting from 10 companies

Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.

Indications focus

from trials led + research topics
Chronic Kidney Disease11 trialsHyperphosphatemia4 trialsIron Deficiencies2 trialsRenal Insufficiency2 trialsRenal Insufficiency, Chronic1 trialESRD / Dialysis

Research focus

OpenAlex concept fingerprint
Parathyroid Disorders and TreatmentsDialysis and Renal Disease ManagementMagnesium in Health and DiseaseVitamin D Research StudiesPotassium and Related Disorders

Drugs & molecules

across trials, industry payments and publications
Vafseogeneric · VadadustatClinical trialsIndustry payments5Publications2Lokelmageneric · Sodium zirconium cyclosilicateClinical trialsIndustry payments1Publications1Parsabivgeneric · EtelcalcetideClinical trialsIndustry payments1Publications1

Works with

trial sponsors and companies reporting payments
Outset Medical IncClinical trialsIndustry payments18Ardelyx, Inc.Clinical trialsIndustry payments15Denver Nephrologists, P.C.Clinical trials7Industry payments

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
287publications

Distinct works indexed by OpenAlex, matched via ORCID; 8 in PubMed.

23,163citations

Total citations across indexed works.

62h-index

Hirsch index (OpenAlex). i10-index 137.

Clinical & industry

trials, payments and federal funding
13clinical trials

Investigator role on registered studies.

View trials
10companies · 2021–2025

Companies reporting payments to CMS. Facts, not judgments.

View payments
0NIH grants

Federally funded research awards.

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

Telephone

Practice address and telephone from the federal NPPES registry.

Sign in to view contact details →

Clinical trials

Updated 27 Aug 2026

Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:

Industry payments

Updated 27 Aug 2026

10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Nervous system

    50%
    Gabapentinoids50%
    Gabapentin100%
    Part D<11 patients
  • Cardiovascular

    50%
    Angiotensin receptor blocker (ARB)50%
    Losartan Potassium100%
    Part D<11 patients

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →

Congress activity

Updated 27 Aug 2026

2 congress contributions (2014–2018) across ASCO, ASH per OpenAlex. The most recent:

Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.

Publications

Updated 27 Aug 2026

Their five most recent publications, matched to their ORCID record and linked to PubMed.

Network

Updated 27 Aug 2026

The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.

Online presence

Updated 27 Aug 2026

This person's own public accounts first, then places where others mention them. Two different things, listed separately.

Mentions by others

where others cite or feature them
  • X / Twitter

    ir.ardelyx.com/news-releases/news-release-details/ardelyx-appoints-renowned-nephrologist-geoffrey-block-md-its

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ir.ardelyx.com
  • Other

    usrenalcare.com/bio/geoffrey-a-block

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →usrenalcare.com

We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.

Background & recognition

Updated 27 Aug 2026

Credentials, appointments and honors, newest first, each linked to the public source it came from.

Education

degrees and training on record

Editorial & leadership roles

journal and society appointments
  • Member

    Board of Directors, Ardelyx, Inc.

    2019
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →prnewswire.com
  • Manuscript reviewer (since 2000) for New England Journal of Medicine

    Journal of the American Medical Association, Journal of the American Society of Nephrology, and American Journal of Kidney Disease

    2000
    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →usrenalcare.com
  • Member

    Scientific Advisory Board, R1 Therapeutics (supporting AP306 development for chronic kidney disease)

    verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →globenewswire.com

Awards & honors

honors on the public record

Secondary affiliations

appointments beyond the home institution
1 more affiliation behind the reveal.Reveal →

Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.

Similar KOLs

Other experts from the same institution or the same specialty.